Expression of FAS-L Differs from Primary to Relapsed Low-grade Gliomas and Predicts Progression-free Survival

被引：6

作者：

Werner, Jan-Michael ^{[1
]}

Kuhl, Saskia ^{[1
]}

Stavrinou, Pantelis ^{[1
]}

Roehn, Gabriele ^{[1
]}

Krischek, Boris ^{[1
]}

Blau, Tobias ^{[2
]}

Goldbrunner, Roland ^{[1
]}

Timmer, Marco ^{[1
]}

机构：

[1] Univ Hosp Cologne, Ctr Neurosurg, Dept Gen Neurosurg, Kerpener Str 62, D-50937 Cologne, Germany

[2] Univ Hosp Cologne, Ctr Neurosurg, Inst Neuropathol, Cologne, Germany

来源：

ANTICANCER RESEARCH | 2017年 / 37卷 / 12期

关键词：

Glioma; FAS; FAS-L; low-grade glioma; LGG; CD95; CD95L; GLIOBLASTOMA; APOPTOSIS; DEATH; ASTROCYTOMAS; LIGAND;

D O I：

10.21873/anticanres.12121

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The tumor necrosis factor FAS is overexpressed in high-grade gliomas (HGG). Only little is known about FAS or FAS ligand (FAS-L) in low-grade gliomas (LGG). We explored FAS/FAS-L expression in LGG, focusing on differences in primary and relapsed LGG and on its prognostic value. Patients and Methods: A total of 133 glioma samples (73 LGG, 60 HGG) were collected. The LGG samples included 15 matched pairs of primary and relapsed tumors. RT-PCR was performed to measure FAS/FAS-L expression, using subunit A, flavoprotein variant (SDHA) as housekeeper. Clinical data included progression free-(PFS) and overall survival (OS). Results: LGG showed significantly lower FAS but higher FAS-L expression than HGG. The FAS-L expression was higher in primary compared to relapsed LGG and had a positive prognostic value concerning PFS (median 45.20 vs. 31.37 months). Conclusion: FAS-L could act as a prognostic marker and potential target in primary LGG.

引用

页码：6639 / 6648

页数：10

共 17 条

[1]

Ehrmann J, 2000, NEOPLASMA, V47, P151

[2]

Eisele G, 2013, ANTICANCER RES, V33, P3563

[3] APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo [J].

Eisele, Guenter ;

Roth, Patrick ;

Hasenbach, Kathy ;

Aulwurm, Steffen ;

Wolpert, Fabian ;

Tabatabai, Ghazaleh ;

Wick, Wolfgang ;

Weller, Michael .

NEURO-ONCOLOGY, 2011, 13 (02) :155-164

[4] Apoptosis and survival in high-grade astrocytomas as related to tumor fas (APO-1/CD95) expression [J].

Frankel, B ;

Longo, SL ;

Leach, C ;

Canute, GW ;

Ryken, TC .

JOURNAL OF NEURO-ONCOLOGY, 2002, 59 (01) :27-34

[5] Changing incidence and improved survival of gliomas [J].

Ho, Vincent K. Y. ;

Reijneveld, Jaap C. ;

Enting, Roelien H. ;

Bienfait, Henri P. ;

Robe, Pierre ;

Baumert, Brigitta G. ;

Visser, Otto .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) :2309-2318

[6] THE POLYPEPTIDE ENCODED BY THE CDNA FOR HUMAN CELL-SURFACE ANTIGEN FAS CAN MEDIATE APOPTOSIS [J].

ITOH, N ;

YONEHARA, S ;

ISHII, A ;

YONEHARA, M ;

MIZUSHIMA, S ;

SAMESHIMA, M ;

HASE, A ;

SETO, Y ;

NAGATA, S .

CELL, 1991, 66 (02) :233-243

[7] THE FAS DEATH FACTOR [J].

NAGATA, S ;

GOLSTEIN, P .

SCIENCE, 1995, 267 (5203) :1449-1456

[8] The Definition of Primary and Secondary Glioblastoma [J].

Ohgaki, Hiroko ;

Kleihues, Paul .

CLINICAL CANCER RESEARCH, 2013, 19 (04) :764-772

[9] Prognostic factors for survival in adult patients with cerebral low-grade glioma [J].

Pignatti, F ;

van den Bent, M ;

Curran, D ;

Debruyne, C ;

Sylvester, R ;

Therasse, P ;

Afra, D ;

Cornu, P ;

Bolla, M ;

Vecht, C ;

Karim, ABMF .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) :2076-2084

[10] Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme [J].

Polivka, Jiri, Jr. ;

Polivka, Jiri ;

Holubec, Lubos ;

Kubikova, Tereza ;

Priban, Vladimir ;

Hes, Ondrej ;

Pivovarcikova, Kristyna ;

Treskova, Inka .

ANTICANCER RESEARCH, 2017, 37 (01) :21-33

← 1 2 →